Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Other Accumulated Expenses (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Other Accumulated Expenses for 4 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • Quarterly Other Accumulated Expenses rose 1132.14% to $1.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Sep 2025, up 1132.14% year-over-year, with the annual reading at $75000.0 for FY2024, 167.86% up from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $1.0 million at Century Therapeutics, up from $49000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $1.0 million in Q3 2025, with the low at $11000.0 in Q2 2023.
  • Average Other Accumulated Expenses over 4 years is $164000.0, with a median of $75000.0 recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses crashed 88.14% in 2023, then skyrocketed 1132.14% in 2025.
  • Over 4 years, Other Accumulated Expenses stood at $236000.0 in 2022, then plummeted by 88.14% to $28000.0 in 2023, then soared by 167.86% to $75000.0 in 2024, then soared by 1280.0% to $1.0 million in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $1.0 million, $49000.0, and $111000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.